Literature DB >> 31109701

Intermittent abortive reactivation of Epstein-Barr virus during the progression of nasopharyngeal cancer as indicated by elevated antibody levels.

Xiaoyi Guo1, Tingdong Li1, Fugui Li2, Yarui Xu1, Han Wang1, Weimin Cheng2, Jiabao Tang1, Guoliang Zhou1, Honglin Chen3, Munhon Ng1, Mingfang Ji4, Shengxiang Ge5, Ningshao Xia1.   

Abstract

The development of nasopharyngeal carcinoma (NPC), a common cancer in Southeastern Asia, is closely associated with Epstein-Barr virus (EBV) infection; however, the aetiological role of EBV in NPC pathogenesis remains enigmatic. The life cycle of EBV in NPC patients is defined as latency II, while the antibodies specific to lytic phase proteins, as well as lytic genes, were highly expressed in NPC patients. The correlation between antibody levels and the progression of NPC has been reported in some studies; however, most of these studies focused on IgA antibodies, and the results in different articles were not consistent. In this study, we concurrently determined the levels of IgA and IgG antibodies specific to six purified recombinant EBV antigens associated with different replication statuses of EBV: EBNA1 associated with latency II; the non-structural antigens Zta, TK, EA-D and EA-R associated with immediate-early and early lytic phases; and the EBV matrix protein VCA p18, which is involved in late lytic phase. Levels of antibodies specific to immediate-early and early antigens were correlated with the tumour progression, especially tumour size. The levels of antibodies specific to some lytic phase antigens were also correlated with lymph node inclusion and metastasis. However, the antibody specific to the latency II antigen EBNA1 was not correlated with either tumour size or metastasis. Consistent with previous transcriptome studies, the results suggested both the expression of lytic phase genes at the protein level and the intermittent reactivation of EBV in NPC patients.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibody profile; Epstein-Barr virus; Nasopharyngeal carcinoma; Stage; Tumour progression

Mesh:

Substances:

Year:  2019        PMID: 31109701     DOI: 10.1016/j.oraloncology.2019.04.024

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  9 in total

1.  Atypical immune response to Epstein-Barr virus in major depressive disorder.

Authors:  Lorraine Jones-Brando; Faith Dickerson; Glen Ford; Cassie Stallings; Andrea Origoni; Emily Katsafanas; Kevin Sweeney; Amalia Squire; Sunil Khushalani; Robert Yolken
Journal:  J Affect Disord       Date:  2019-11-30       Impact factor: 4.839

Review 2.  Interplay between Epstein-Barr virus infection and environmental xenobiotic exposure in cancer.

Authors:  Francisco Aguayo; Enrique Boccardo; Alejandro Corvalán; Gloria M Calaf; Rancés Blanco
Journal:  Infect Agent Cancer       Date:  2021-06-30       Impact factor: 2.965

Review 3.  Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Human Herpesviruses Are Back!

Authors:  Maria Eugenia Ariza
Journal:  Biomolecules       Date:  2021-01-29

Review 4.  Role of BamHI-A Rightward Frame 1 in Epstein-Barr Virus-Associated Epithelial Malignancies.

Authors:  Rancés Blanco; Francisco Aguayo
Journal:  Biology (Basel)       Date:  2020-12-11

5.  Examination of control asymptomatic cohorts reveals heightened anti-EBV and HHV-6 A/B dUTPase antibodies in the aging populations.

Authors:  Khaled Alharshawi; Brandon Cox; Maria E Ariza
Journal:  J Med Virol       Date:  2022-03-26       Impact factor: 20.693

6.  Impact of Pre-Existing Chronic Viral Infection and Reactivation on the Development of Long COVID.

Authors:  Michael J Peluso; Tyler-Marie Deveau; Sadie E Munter; Dylan Ryder; Amanda Buck; Gabriele Beck-Engeser; Fay Chan; Scott Lu; Sarah A Goldberg; Rebecca Hoh; Viva Tai; Leonel Torres; Nikita S Iyer; Monika Deswal; Lynn H Ngo; Melissa Buitrago; Antonio Rodriguez; Jessica Y Chen; Brandon C Yee; Ahmed Chenna; John W Winslow; Christos J Petropoulos; Amelia N Deitchman; Joanna Hellmuth; Matthew A Spinelli; Matthew S Durstenfeld; Priscilla Y Hsue; J Daniel Kelly; Jeffrey N Martin; Steven G Deeks; Peter W Hunt; Timothy J Henrich
Journal:  medRxiv       Date:  2022-07-22

7.  From Anti-EBV Immune Responses to the EBV Diseasome via Cross-reactivity.

Authors:  Darja Kanduc; Yehuda Shoenfeld
Journal:  Glob Med Genet       Date:  2020-08-31

8.  Efficacy of Chemiluminescence Immunoassays on VCA-IgA and EBNA1-IgA Antibodies of Epstein-Barr Virus in Diagnosing Nasopharyngeal Carcinoma.

Authors:  Xia Yu; Fugui Li; Weimin Cheng; Biaohua Wu; Huiyun Fang; Fuzhen Xia; Yijun Gong; Wenjing Yu; Pu Liao; Youde Cao; Fenghua Yang; Hong Zhu; Jiang Li; Yajun Huang; Liying Gan; Lei Zhang; Yonggang Lou; Mingfang Ji
Journal:  J Cancer       Date:  2020-10-18       Impact factor: 4.207

9.  Association between HLA alleles and Epstein-Barr virus Zta-IgA serological status in healthy males from southern China.

Authors:  Lei-Lei Yuan; Chang-Mi Deng; Wen-Qiong Xue; Yong-Qiao He; Tong-Min Wang; Jiang-Bo Zhang; Da-Wei Yang; Ting Zhou; Zi-Yi Wu; Ying Liao; Mei-Qi Zheng; Dan-Hua Li; Lian-Jing Cao; Yi-Jing Jia; Wen-Li Zhang; Ruo-Wen Xiao; Lu-Ting Luo; Xia-Ting Tong; Yan-Xia Wu; Jing-Wen Huang; Wei-Hua Jia
Journal:  J Gene Med       Date:  2021-07-06       Impact factor: 4.565

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.